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Kinetics and efficacy of deferoxamine in iron-overloaded hemodialysis
patients. We evaluated the kinetics and efficacy of deferoxamine (DFO)
therapy in iron-overloaded hemodialysis patients. Concentrations of
DFO and its chelated product, feroxamine (Fx), were assessed follow-
ing single-dose DFO administration in twelve patients, and during
chronic therapy over one year's time in eight, similarly iron-overloaded
dialysis patients. A functional assay which relies on measurements of
iron and iron binding capacity for the determination of Fx and DFO,
respectively, was corroborated with liquid chromatographic tech-
niques. Half-life measurements were also corroborated with tracer
doses of '4C-DFO and 59Fe-feroxamine. Intradialytic DFO half-life (2.3
1.1 h) was considerably less than interdialytic half-life (26 I hr).
Unbound DFO was found to persist throughout the interdialytic period.
Calculation of the percent saturation of the DFO dose indicated that
only 30% of a given dose is chelated. The amount of iron removed
dialytically was approximately 13.1 2.7 mg per dialysis session.
Chronic DFO administration was also shown to enhance gastrointesti-
nal iron excretion threefold. However, ferritin levels decreased by only
25% after one year of thrice-weekly DFO therapy. We conclude that
DFO therapy for iron-overloaded hemodialysis patients is optimized by
its administration interdialytically, and results in slow removal of iron,
via both dialytic and gastrointestinal routes.
Recent insights into trace metal metabolism in end-stage
renal disease patients have implicated a role for aluminum (Al)
in the evolution of bone [1], central nervous system [2], and
hematopoietic disease [3], and a circumstantial role for iron (Fe)
in visceral organ failure [4] and bone disease [5]. As the
spectrum of metal-related disease has broadened, deferoxamine
(DFO) has been employed as primary therapy with increasing
frequency [1, 6—8]. At present, it is estimated that nearly 5% of
dialysis patients receive chronic DFO treatment for either
Al-related disease or Fe overload. Nevertheless, pharmacoki-
netics and dosing studies of DFO are lacking, primarily because
of the methodological difficulties of measuring DFO and its
chelated compound; this may have contributed to recent re-
ports of dose-related DFO toxicity [9, 10].
Although the incidence of aluminum-induced bone disease in
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the hemodialysis patient population in general is greater than
iron induced disease, we chose to study DFO kinetics in iron
overloaded patients because of the high incidence of transfu-
sional Fe overload in our patient population [11], and because
of increasing concern about the morbidity associated with Fe
overload [11—13], and finally because the functional assay
developed for DFO and feroxamine (Fx) relies on the measure-
ment of iron and iron binding capacity before and after DFO
infusion. Since many of these patients were long-term dialysis
patients and had chelatable aluminum, we also studied concom-
itant mobilization kinetics of iron and aluminum with chronic
DFO administration.
Methods
Protocols
Patients were enrolled in the following study protocols after
informed consent was obtained. All protocols had been ap-
proved previously by the Committees on Human Subjects at
Brigham and Women's Hospital, and The Kidney Center,
Boston.
Acute studies. Patients received 24.3 2.5 mg/kg of DFO
(Desferal, CIBA-Geigy) in normal saline, administered intrave-
nously over a 30 minute period. To assess the feasibility of
intradialytic administration of DFO, DFO was administered to
four patients between 60 and 120 minutes prior to initiation of
dialysis. Serum and dialysate concentrations of DFO and Fx
were obtained at intervals following initiation of dialysis for up
to four hours.
In five patients, a single dose of DFO was administered
post-hemodialysis. Serum and dialysate DFO and Fx were
followed sequentially during the interdialytic period for up to 48
hours post-infusion.
Tracer amounts of '4C-labelled DFO (CIBA-Geigy, Basel,
Switzerland) and 59Fe-labelled Fx were administered intrave-
nously to four of the above five patients immediately post-
dialysis and counts followed over a 60 hour cycle, which
included a hemodialysis session. The decay in the counts of
these stable isotopes was used to calculate half-lives of these
compounds.
Chronic studies. Patients received intravenous DFO (mean
dose 42.8 4.2 mg/kg) over 30 to 40 minutes following the
termination of each dialysis three times weekly. Blood was
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Fig. 2. Schema for the chemical assay of
deferoxamine (DFO) and feroxamine (Ex).
Fe0 Iron concentration after DFO infusion.
Fe0 = Iron concentration before DFO
infusion. UIBC0 = Unbound iron binding
capacity after DFO infusion. UIBC0 =
Unbound iron binding capacity before DFO
infusion.
sampled for Fe, total Fe binding capacity (TIBC) and aluminum
at baseline (prior to infusion of DFO) and at 15, 30, and 60
minutes following the conclusion of infusion. These baseline
and DFO-stimulated measurements were repeated after the
third and ninth treatments, and after three months and six
months of chronic DFO infusion treatments. After the sixth
month treatment, therapy was discontinued for a period aver-
aging two months so that DFO-related and DFO-unrelated
changes may be compared. DFO was re-initiated in an identical
fashion thereafter for another period of six months (Fig. 1). In
six patients, stool collections of three to seven days duration
were obtained before inception of therapy, and after chronic
therapy had begun.
Assays
DFO and Fx. These were measured by the following func-
tional assay: duplicate pre-treatment determinations of iron and
iron binding capacity were made in each patient (method of
measurement, below). After infusion of DFO, serial values of
iron and iron-binding capacity were determined at various time
intervals. The serum Fx and DFO were derived from these
values according to the scheme illustrated in Figure 2, and is
based on the hypothesis that infusion of DFO leads to the
mobilization of iron from body stores. The increment in serum
iron over pre-infusion values (Fe — Fe0) therefore represents
newly chelated iron, or Fx. In addition, unbound DFO results in
an increment in total iron binding capacity (TIBC). This incre-
ment was converted to its DFO equivalent by multiplying it by
the ratio of the atomic weights of DFO to Fe (10,7:1). Mobilized
DFO complexed Al [DFO5AIJ was similarly derived from the
increment in serum Al following DFO infusion.
Serum iron was assessed in duplicate samples using flame
atomic absorption spectroscopy (Perkin-Elmer 5000 Atomic
Absorption Spectrometer, Norwalk, Connecticut, USA). To
determine total iron-binding capacity, excess iron was added to
each duplicate aliquot, followed by precipitation of non-bound
iron with 100 mg Mg2CO3. This mixture was vortexed for 30
minutes and then spun at 3000 rpm for 10 minutes. Supernatant
was removed for iron analysis as described above. Serum Al
was measured by graphite furnace atomic absorption spectros-
copy utilizing a Zeeman background compensator. Ferritins
were measured utilizing the Ferrizyme Diagnostic Kit (Abbott,
EIA, North Chicago, Illinois, USA).
Dialysate. Dialysate samples were collected in iron-free
tubes at 15, 30, 45, 60, 90, 120 and 240 minutes post-initiation of
dialysis from inlet and outlet of dialysate ports. These were
assayed for dialysate iron. Total chelated iron removed in the
course of a four hour dialysis was calculated by integration of
the net serial concentrations of dialysate iron over the total
volume of dialysate in a given period of time.
HPLC studies. Serum samples from patients and controls
dosed with known concentrations of DFO and Fx were run
simultaneously by the atomic absorption method outlined
above and by high pressure liquid chromatography (HPLC),
(Shimadzu LC-6A, Kyoto, Japan), with an all glass column and
plastic lined injector (RPIC-C18-Sit, Dionex, Sunnyvale, Cali-
fornia, LISA), and UV detector at 220 nm. The solvent (80%
buffer, 20% acetonitrile, pH adjusted to 3.0 with phosphoric
acid) was used at a flow rate of 1 mI/minute. Plasma sample
preparation included deproteination by adding cold methanol to
plasma at a ratio of 4:1 (vol/vol), centrifugation at 10,000 g for
15 minutes, then drying up the supernatant under N2 in a rotary
evaporator. The sample was then brought up in a solution of
acetonitrile and buffer (20:80, vol/vol). Further purification of
the sample was done by a preparative column (Bond-Elut, C-18)
and eluted with a mixture of buffer and acetonitrile (2 ml at a
vol/vol ratio of 98/2 huffer/acetonitrile, then 1 ml at a ratio of
80/20 vol/vol buffer/acetonitrile). Typical retention time for Fx
was 3.4 minutes and for DFO was 5.3 minutes. Sample concen-
tration was calculated from the area under the peak, measured
by the peak integrator (Shimadzu C-R3A).
Mean recovery by this method was 82 2.5% for both DFO
and Fx. Because of DFO's high binding affinity to iron, any
trace contamination in the pathway of the sample is readily
chelated by DFO to form Fx. Therefore prior to injection of
samples, at least 500 mg of DFO was used to rinse the
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Fig. 1. Chronic DFO timetable for testing.
Arrows indicate testing after 1st, 3rd and 9th
dose of DFO, then at 3 and 6 months; this is
followed by a 2 month hiatus and retesting in
a similar fashion.
Feroxamine Fe,, — Fe0 (tg/dl)
Deferoxamine = [UIBC,, UIBCQ (tg of bound Fe/dI)] M.W. deferoxamineMW. Fe
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Table 1. Patient characatenstics: Acute study
Sex Age Wt DT Hct Nx Ferr % Sat Tx OT PT ALK Fe/wt
F
F
F
M
M
M
M
M
F
F
M
F
45
28
26
36
46
41
40
36
25
24
46
27
39
51
40
60
64
71
64
54
54
44
45
136
67
144
168
154
132
156
40
38
72
180
120
24
24
27
26
23
27
20
27
20
15.5
21.5
24
y
n
y
y
y
y
y
n
y
y
y
n
11,200
7,400
9,100
19,360
9,000
3,550
7,000
8,400
7,000
6,000
3,000
7,000
85
76
78
85
75
89
100
73
97
87
96
—
235
159
217
356
310
158
550
93
77
100
360
100
41
80
114
53
29
35
42
46
54
52
27
222
128
128
290
80
37
54
9
27
63
84
39
479
197
758
366
575
643
343
44
430
70
145
1965
1205
623
1085
1187
969
445
1719
344
285
455
6/6 35 53.3 117 23.3 8,168 88.3 238 56.1 96.8 501 831
Abbreviations are: Wt, weight (kg); DT, time on dialysis (months); Nx, nephrectomy; Ferr, ferritin concentration (ng/ml); % Sat, % saturation
of total iron binding capacity; Tx, number of units of RBC transfusions; OT, serum glutamic oxaloacetic transaminase (LU) (N = 4-40 LU); PT,
serum glutamic pyruvic transaminase (LU) (N = 6—55 IU); Alk, alkaline phosphatase (IU) (N = 40—110 IU); Fe/wt, iron burden in mg/kg body
weight.
Table 2. Patient characteristics : Chronic study
Age Sex Wt DT % Sat Fe/wt Ferr Nx Tx
50
27
33
46
36
44
35
28
37 4 +— 3 2.
M
F
F
F
F
M
F
F
51
52.8
32.5
36.5
44.4
79
50.5
51.5
49.8 5.3
57
80
77
159
126
152
120
74
105.6 14.6
98
98
89
97
92
100
85
100
94.9 2.1
1133
822
652
2066
1023
461
762
988 214
20,100
20,000
12,661
13,178
11,304
6,805
10,531
23,350
14,731 2,165
y
n
n
y
1/2
y
1/2
n
289
217
106
377
227
182
192
227 79.6
Abbreviations are the same as those listed in Table 1.
glass-lined sample pathway [14]. Subsequently, the column was
stabilized with the solvent system until a stable baseline was
obtained in the detector.
Stools. For Fe analysis, stools were collected in aluminum
cans, lyophilized, and dry weights determined. Aliquots of
lyophilized sample were then dissolved in concentrated sulfuric
acid, and Fe content determined by flame atomic absorption
spectroscopy.
Statistics. Statistical analysis was performed utilizing t-test
for differences of means except where otherwise noted. All
results are expressed as mean
Patients
Iron overloaded patients for acute and chronic DFO infusion
were selected based on biochemical (ferritin concentrations >
3000 ng/ml), clinical (melanoderma, new onset of diabetes) or
radiological (abdominal CT scan indicating high attenuation
coefficient for the liver and spleen) evidence. The characteris-
tics of the patients for both acute and chronic studies are shown
in Table 1 and 2, respectively. None of the patients studied in
either acute or chronic protocols had a history of ethanol abuse,
thalassemia, sickle cell disease, or hepatitis B. All patients
underwent their hemodialysis treatments using cuprophane
dialyzers with blood and dialysate flow rates of 300 mI/mm and
500 ml/min, respectively. The transfusional Fe load for each
patient was derived from available outpatient dialytic charts,
inpatient records, and blood bank files. Fe burden was calcu-
lated by multiplying the number of transfusions since inception
of hemodialysis by 200 mg Fe for each unit (approximately 1 mg
of Fe/mI of packed red blood cells). Patients were maintained
on their usual medications, including those who were on
aluminum containing phosphate binders. However, an attempt
was made to reduce the frequency of transfusions to a mini-
mum.
Results
Acute studies
Mean serum concentrations of DFO and Fx with DFO
infusion after termination of dialysis are shown in Figure 3A
and B. DFO concentration rose rapidly to 27.9 2.84 mg/l
within ten minutes, then to 31.9 3.1 mg/I at the end of one
hour (Fig. 3A), and declined thereafter as shown in Figure 3B.
Note that throughout the interdialytic period of 48 hours,
unbound DFO persists in the plasma.
Although mobilization of iron as Fx occurs as early as one
hour after completion of DFO infusion, as shown in Figure 3A,
the highest concentration (3.99 0.46 mg/liter) was measured
approximately 20 hours post-infusion; subsequently Fx de-
clined slowly over the remainder of the interdialytic period in
the absence of any dialytic removal (Fig. 3B).
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Fig. 3A. Concentration of unbound DFO (O----O) and
Fx (S •) 60 minutes after acute infusion of DFO
interdialytically. B. Concentration of unbound DFO and
feroxamine up to 48 hours after acute infusion of DFO.
Note the presence of unbound DFO throughout the
interdialytic period.
Arteriovenous differences of Fx across the dialyzer were
within the experimental error of iron measurement, and thus
accurate dialytic clearance of Fx could not be obtained. There-
fore, in five patients who received DFO immediately after a
dialysis session, net Fx appearance in the dialysate during the
subsequent treatment was quantitated, revealing mean removal
of 13.1 2.7 mg (N = 6) of elemental iron during a four-hour
dialysis period. There was a modest decrease in the amount of
Fe excreted with dialysis time (3.6 0.85 mg during 1st hour,
3.3 1.6 mg during 2nd hour, 3.2 mg 1.6 during 3rd hour and
2.95 1.7 mg during the 4th hour) that was not statistically
significant. Clearance of Fx, calculated from the ratio of the
total flux to the initial serum concentration was 26.8 6.3
mi/mm.
"Chemical" half-lives of DFO and Fx in vivo were calculated
from the changes in serum concentration during the intradia-
lytic and interdialytic periods (Table 3) according to the func-
tional assay described previously. Intradialytic half-lives for
DFO and Fx were 2.0 1.3 hours and 4.1 1.4 hours,
respectively; the interdialytic half-lives of DFO and Fx were
25.6 3.6 and 24.5 8.0 hours, respectively. These measure-
Table 3. Half lives of deferoxamine and feroxamine
Fun
Intradialytic hrs
ctional Isotopic
Interdialytic
Functional
hrs
Isotopic
2.0±1.3 2.3± 1.1 25.6±3.6 26±1
4.1±1.4 3.6± 1.4 24.5±8 28±3
DFx
Fx
With intact renal function [11]: T1,2 deferoxamine 0.8 1.7 hours
T112 feroxamine 0.5 1.0 hours
ments were corroborated by determining the half-lives of '4C-
labelled IWO and 59Fe-labelled Fx over 60 hours, including a
dialysis session. As noted in Table 3, the results are in close
agreement. Note, however, that with both the chemical and
isotopic determination of DFO half-life, the decrease in the
concentration of DFO does not take into account the fraction of
DFO that diffuses intracellularly or the fraction that is con-
verted to Es concomitant with dialysis; both these factors will
lead to an underestimate of DFO half-life determination.
Correlations of the concentration of DFO and Fx measured
by the functional assay (using the atomic absorption method) to
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Time post-DFO infusion, minutes
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Fig. 5. Concentration of Fx 60 minutes
following administration of DFO the 1st, 3rd
and 9th time and at 3 and 6 months following
the chronic administration of DFO (A) and
after restarting DFO (B).*P < 0.05.
those measured by the HPLC are shown in Figure 4A and B,
respectively. It can be seen that there is close correspondence
of the values of DFO and Fx levels obtained by each method (r
= 0.89, P < 0.01 for DFO and r = 0.91, P <0.001 for Fx).
Chronic studies
DFO, Fx and ferritin measurements. The amount of Fx
formed 60 minutes following termination of DFO infusion is
shown in Figure 5A for the 1st, 3rd and 9th treatment, at the 3rd
and 6th month. Sixty minutes after the end of the first DFO
infusion, Fx concentration was 1.88 0.36 mg/liter, and
plateaued by the third treatment at 2.97 0.42 mg/liter, and
varied only slightly throughout the first six months of therapy.
In the six patients examined to date in whom DFO was
restarted in an identical fashion following two months off DFO
therapy (Fig. 5B), the amount of mobilized Fe (Fx) increased
minimally relative to the corresponding first six-month period.
During this second period, a slight but significant increase was
noted at the ninth treatment compared to the first treatment.
When examined concurrently, serum DFO concentration
remained stable throughout the first six-month experimental
period (Fig. 6A) at levels between 68.2 16.4 mg/liter one hour
after the first infusion to 104.6 38.2 mg/liter at the six-month
sampling interval. Similar levels were observed following rein-
itiation of therapy after the two month hiatus (Fig. 6B).
Calculation of the contribution of bound to total circulating
DFO ([DFO*FeJ/[DFO*Fe + DFO*Al + DFO unbound]) reveal-
ed that circulating DFO remained approximately 30% saturated
with Fe at these sampling intervals throughout the entire study
period, both before and after restarting drug, even after alumi-
num mobilization was accounted for.
Daily stool collections before and after inception of therapy
BA
CD
90
80
a.
7060
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Deferoxamine concentration
by atomic absorption
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Feroxamine concentration
by atomic absorption
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Fig. 4. The correlation of HPLC and
chemical assay for DFO (A) and Fx (B).
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Fig. 6. Concentration of DFO 60 minutes following its administration
the 1st, 3rd and 9th time and at 3 and 6 months following its chronic
administration (A). After a 2 months hiatus, chronic DFO was restarted
and similar measurements were performed (B).
demonstrated a threefold increase in Fe excretion over baseline
in response to DFO from 4.9 0.9 to 14.4 3.3 mg/day (P C
.005).
The change in ferritin concentration (expressed as the per-
cent of the value obtained at the first treatment with DFO) is
shown in Figure 7. During the course of six months' treatment,
serum ferritin fell slowly. By 12 months of therapy, ferritin
declined by 25.4 8.25% (P C 0.05 by paired 1-test).
Aluminum measurements. Serum Al was profiled in a similar
fashion to Fx, with increments over pretreatment values con-
sidered to be chelated aluminum. Aluminum mobilization dur-
ing the first period rose rapidly by the third treatment to 0.295
0.135 mg/liter and fell to very low levels by six months (0.10
.15 mg/liter; Fig. 8A). Following two month cessation and
subsequent reinstitution of DFO therapy, mobilizable Al reap-
peared (Fig. 8B), peaking again by the third treatment at 0.145
0.5 mg/liter; this was significantly lower from the correspond-
ing level during the first six months (P C 0.05).
The stoichiometry of combined Fe and Al mobilization was
derived from the micromoles of Fe and Al mobilized simulta-
neously at each time point, calculated from the mean weight-
adjusted values previously derived for each. Molar ratios of
Fe:Al mobilized ranged from 7:1 at the beginning of therapy to
140:1 at the end of the first experimental period.
Complications of therapy. Few complications were noted in
the eight patients treated chronically. Dose and infusion rate-
related hypotension (generally at rates exceeding 50 to 60
mg/mm) were occasionally encountered and responded either to
Fig. 7. Percent reduction of ferritin concentration as a function of
chronic DFO administration. < 0.05 by paired t-test.
saline infusion or reduction of infusion rate. There were no
incidences of infections or fever. All patients received routine
ophthalmological examinations at the beginning of the study.
There were no complaints of visual or auditory changes in any
of the patients except for one patient who required temporary
discontinuation of therapy at six months because of an ischemic
retinal infarct documented by focal visual field loss. No evi-
dence of pigment epithelial change or optic nerve head damage
was noted, however, and treatment was resumed uneventfully
after a short hiatus without further visual side effects.
Discussion
Studies designed to assess the kinetics and efficacy of chela-
tion therapy using deferoxamine have been limited by diffi-
culties in quantitating levels of bound and free DFO. The
functional assay described here allows the determination of
both free DFO as well as iron (and aluminum) bound DFO.
Although this proportion of unbound DFO is calculated after
taking into account the DFO bound to aluminum, it is possible
that this functional assay may over-estimate the amount of
unbound DFO since the in vitro addition of iron may displace
complexes of DFO with other metal ions. However, the relative
affinity of DFO to trivalent ions is orders of magnitude greater
than it is for divalent ions 1151 and DFO chelation has not been
reported to lead to depletion or changes in the concentrations of
most common divalent ions [16, 17]. In addition, the retention
time of "unbound" DFO by HPLC using aqueous and non-
uremic plasma samples were similar, suggesting that DFO does
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Fig. 8. Serum aluminum concentration with chronic DFO administra-
tion. Note recurrence of high levels of aluminum after 2 months hiatus.
*D < 0.05. Abbreviations are the same as in Fig. 6.
not bind other metallic entities. This functional assay has also
been validated by the HPLC studies, and yields data corre-
sponding closely to the predicted plasma DFO concentrations
for the total dose infused distributed over total body water.
The results of the study allow several observations concern-
ing the kinetics of DFO. In the first place, despite the great
affinity of DFO to iron in vitro, a large fraction of DFO given to
these heavily iron-overloaded patients remain unbound. The
therapeutic implication of the persistence of unbound DFO is
that dosages of DFO lower than those used in the current study
are likely to be equally effective in chelation of iron (and
probably aluminum) in hemodialysis patients. Although we
have not developed dose dependent kinetics of free and bound
DFO, since approximately 70% of the DFO dose given in this
study remains unbound to either iron or aluminum, a reduction
of the dose administered (such as, 15 to 20 mg/kg) may be
equally effective in the chelation of these metals. It is interest-
ing to note that recent reports have indicated that there was no
significant difference in the aluminum mobilized by a one gram
or two gram dose of DFO in one study [181 and between 2 grams
and 4 grams in another study [19]. Reduction of the proportion
of unbound DFO may also reduce the reported infectious
[20—22], ophthalmic [9] and neurologic [10] side effects of DFO
that are likely to be dose dependent. Second, the relatively low
intradialytic half-life of DFO, measured both isotopically and
chemically, favor its administration at the conclusion of a
dialysis treatment or if convenient, one day prior to dialysis [19,
23]. Intramuscular injections may also be advantageous in
limiting dialytic removal of DFO and maximizing Fx formation
[18].
Dialytic clearance of Fe (as Fx) with cuprophane dialyzers
has been reported in vitro variably between 5 and 20 ml/min,
and total (chelated) Fe loss between 2.0 and 7.5 mg/hr [7, 24]. In
this study, the dialytic clearance of Fx was found to be
approximately 27 ml/min using cuprophane membranes,
whereas the total (chelated) Fe loss calculated from the appear-
ance of iron in the dialysate was approximately 3.3 mg/hr, in
agreement with previously reported results [25]. The decline in
serum Fx concentration in the absence of dialytic clearance is
consistent with the notion that extradialytic removal occurs
[25—29]. Evidence that Fx present in the serum can be excreted
in the stool is indicated by the threefold increase in stool Fe
excretion documented in the chronic studies, as well as the
presence of 59Fe counts in the stools of patients given 59Fe-
labelled Fx. Thus, coupled with an increment in gastrointestinal
excretion of 10 mglday over baseline following initiation of
therapy, quantitation of dialytic and extra-renal excretion of Fx
suggests that over a 12 month period of DFO therapy an
estimated total of 5.5 grams of Fe would be removed with this
therapeutic regimen [25]. Since the average total body Fe
burden in these patients is approximately 50 grams, ten years of
treatment would be theoretically required to reduce the degree
of Fe loading to pre-morbid levels, assuming no further trans-
fusion. Although this DFO-induced Fe removal probably ac-
counts for the decrease in ferritin, since there was no decrease
in ferritin concentration during the two-month drug free hiatus
(Fig. 7), nevertheless, alternative methods, such as the use of
high flux dialyzers which are reported to have a clearance of 80
ml/min for chelated Al [30, 31] or the use of hemoperfusion
system [32—34] or the combined use of erythropoietin and
phlebotomy [35], may offer a more efficient therapy.
Many of the long-term hemodialysis patients have concomi-
tant iron and aluminum overload [36], and DFO is used for the
chelation of both metals. The relative affinities of Fe and Al for
DFO have been assessed primarily in vitro [37, 38]. Little
information exists to date, however, describing this relationship
in vivo. In the current studies of this iron-overloaded popula-
tion, the molar ratios of Fe to Al concurrently mobilized by the
same dose of DFO, differ by no greater than 2.5 orders of
magnitude. This ratio is considerably less than the in vitro
affinity, which is reported to be different by nine orders of
magnitude. Plausible hypotheses include alteration in affinity of
one or both cations for DFO by the uremic milieu, or, more
likely, an effect of the degree of organ involvement with one
metal on the size and accessibility of the chelatable pool of the
other. A precise testing of these hypotheses, however, awaits
methodological advances in the quantitation of the respective
metal pool sizes.
In summary, these studies of acute and chronic DFO infusion
in Fe overloaded patients suggest that the optimal time for DFO
infusion is at the end of a dialytic treatment. The presence of a
large fraction of unbound DFO in the face of significant iron
1132 Stivelman ci a!: Deferoxamine and iron overload
overload suggests that doses less than 40 mg/kg are appropriate
and that despite chronic treatment, the amount of Fe removed
by dialytic and extradialytic routes is small. Finally, whereas in
vitro data have revealed a large difference in chelator affinity for
Fe and Al, in vivo data suggest a more modest difference.
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